Literature DB >> 1597519

Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.

S Kakumu1, A Fukatsu, T Shinagawa, S Kurokawa, A Kusakabe.   

Abstract

AIM: To evaluate the role of local interleukin 6 (IL-6) in the pathogenesis of acute and chronic liver disease.
METHODS: The cellular site of IL-6 in cryostat sections of liver from 31 patients with liver disease was examined using indirect immunofluorescence with a monoclonal antibody.
RESULTS: IL-6 staining in sinusoidal endothelial cells was very noticeable and diffusely distributed in the lobules of specimens of acute viral hepatitis. IL-6 expression in endothelial cells, particularly in necrotic areas of hepatocytes, was increased and was accompanied by enhanced expression in Kupffer cells. In contrast, IL-6 staining in infiltrating mononuclear cells was prominent in portal tracts, and the numbers of cytokine positive cells were greater in specimens of chronic active hepatitis compared with chronic persistent hepatitis. In non-specific reactive hepatitis intrahepatic expression of IL-6 was minimal, while in alcoholic liver fibrosis the cytokine distribution in the lobules was similar to that of acute viral hepatitis.
CONCLUSIONS: These results indicate that locally produced IL-6 contributes to the inflammatory process and immunological response in acute and chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597519      PMCID: PMC495302          DOI: 10.1136/jcp.45.5.408

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

2.  Cellular targets and receptors for interleukin-6. I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes.

Authors:  O Sonne; O Davidsen; B K Møller; C Munck Petersen
Journal:  Eur J Clin Invest       Date:  1990-08       Impact factor: 4.686

3.  Interleukin-6 release by rat liver macrophages.

Authors:  K J Busam; T M Bauer; J Bauer; W Gerok; K Decker
Journal:  J Hepatol       Date:  1990-11       Impact factor: 25.083

4.  Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6.

Authors:  B Grubeck-Loebenstein; G Buchan; D Chantry; H Kassal; M Londei; K Pirich; K Barrett; M Turner; W Waldhausl; M Feldmann
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

5.  Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.

Authors:  A Khoruts; L Stahnke; C J McClain; G Logan; J I Allen
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

Review 6.  Effects of cytokines on the liver.

Authors:  T Andus; J Bauer; W Gerok
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

7.  Detection of interleukin-6 and interleukin-1 production in human thyroid epithelial cells by non-radioactive in situ hybridization and immunohistochemical methods.

Authors:  R Q Zheng; E Abney; C Q Chu; M Field; B Grubeck-Loebenstein; R N Maini; M Feldmann
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

8.  Distribution of interleukin-6 in normal and diseased human kidney.

Authors:  A Fukatsu; S Matsuo; H Tamai; N Sakamoto; T Matsuda; T Hirano
Journal:  Lab Invest       Date:  1991-07       Impact factor: 5.662

9.  Heterogeneous lobular distribution of hepatocytes expressing acute-phase genes during the acute inflammatory reaction.

Authors:  D Bernuau; L Legrès; Y Lamri; N Giuily; G Fey; G Feldmann
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts.

Authors:  P B Sehgal; D C Helfgott; U Santhanam; S B Tatter; R H Clarick; J Ghrayeb; L T May
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  7 in total

1.  Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.

Authors:  Liang Ma; Yan-Jun Cai; Lei Yu; Jun-Yan Feng; Juan Wang; Cong Li; Jun-Qi Niu; Yan-Fang Jiang
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

2.  Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

Authors:  N Furusyo; J Hayashi; M Ohmiya; Y Sawayama; Y Kawakami; I Ariyama; N Kinukawa; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

3.  HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta.

Authors:  Caroline H T Hall; Rachel Kassel; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

4.  HBV replication is significantly reduced by IL-6.

Authors:  Tzer-Min Kuo; Cheng-Po Hu; Ya-Ling Chen; Ming-Hsiang Hong; King-Song Jeng; Chun-Chin T Liang; Mong-Liang Chen; Chungming Chang
Journal:  J Biomed Sci       Date:  2009-04-20       Impact factor: 8.410

5.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.

Authors:  B Xu; U Broome; B-G Ericzon; S Sumitran-Holgersson
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

6.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.

Authors:  T Ezure; T Sakamoto; H Tsuji; J G Lunz; N Murase; J J Fung; A J Demetris
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

7.  Hepatitis B Virus Middle Protein Enhances IL-6 Production via p38 MAPK/NF-κB Pathways in an ER Stress-Dependent Manner.

Authors:  Yang-Xia Li; Yan-Li Ren; Hai-Jing Fu; Ling Zou; Ying Yang; Zhi Chen
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.